CN116096746A - 多瘤病毒中和抗体的给药 - Google Patents

多瘤病毒中和抗体的给药 Download PDF

Info

Publication number
CN116096746A
CN116096746A CN202180056557.5A CN202180056557A CN116096746A CN 116096746 A CN116096746 A CN 116096746A CN 202180056557 A CN202180056557 A CN 202180056557A CN 116096746 A CN116096746 A CN 116096746A
Authority
CN
China
Prior art keywords
antibody
antigen
optionally
binding fragment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056557.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·阿本德
M·纳普
S·J·科瓦茨
A·K·帕蒂克
E·特拉吉埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Vera Treatment Co
Original Assignee
Novartis AG
Vera Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Vera Treatment Co filed Critical Novartis AG
Publication of CN116096746A publication Critical patent/CN116096746A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
CN202180056557.5A 2020-06-12 2021-06-11 多瘤病毒中和抗体的给药 Pending CN116096746A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038433P 2020-06-12 2020-06-12
US63/038,433 2020-06-12
PCT/US2021/036923 WO2021252835A1 (en) 2020-06-12 2021-06-11 Dosing of polyomavirus neutralizing antibodies

Publications (1)

Publication Number Publication Date
CN116096746A true CN116096746A (zh) 2023-05-09

Family

ID=78846596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056557.5A Pending CN116096746A (zh) 2020-06-12 2021-06-11 多瘤病毒中和抗体的给药

Country Status (12)

Country Link
US (1) US20230220051A1 (https=)
EP (1) EP4165078A4 (https=)
JP (1) JP2023550672A (https=)
KR (1) KR20230029781A (https=)
CN (1) CN116096746A (https=)
AU (1) AU2021288699A1 (https=)
BR (1) BR112022025020A2 (https=)
CA (1) CA3186736A1 (https=)
IL (1) IL298956A (https=)
MX (1) MX2022015740A (https=)
TW (1) TW202207986A (https=)
WO (1) WO2021252835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105572A1 (en) * 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
KR20230029781A (ko) 2023-03-03
TW202207986A (zh) 2022-03-01
CA3186736A1 (en) 2021-12-16
AU2021288699A1 (en) 2023-02-09
WO2021252835A1 (en) 2021-12-16
JP2023550672A (ja) 2023-12-05
EP4165078A1 (en) 2023-04-19
MX2022015740A (es) 2023-03-14
US20230220051A1 (en) 2023-07-13
EP4165078A4 (en) 2024-07-17
IL298956A (en) 2023-02-01
BR112022025020A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
JP7041708B2 (ja) ウイルス性肺炎治療のためのＣ５ａの阻害剤
US10858425B2 (en) Pan-ELR+ CXC chemokine antibodies
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
ES2993153T3 (en) Pan elr+ cxc chemokine antibodies
JP7843248B2 (ja) ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
HK1249427A1 (zh) 关节炎治疗
JP2024537163A (ja) 肥満細胞関連障害の治療
JP2022528230A (ja) Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
NL2020520B1 (en) Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR20250133727A (ko) 갑상선 안구 질환을 치료하기 위한 항-IL-11Rα 항체
WO2022051223A1 (en) Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
US20230220051A1 (en) Dosing of polyomavirus neutralizing antibodies
CN114786717B (zh) 稳定的水性抗-tfpi抗体制剂
TW202313105A (zh) 與貝伐單抗的抗葉酸受體結合物組合療法
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
KR20250164827A (ko) SJS/TEN 질환의 치료에서 항-Fas 리간드 (FasL) 항체
CN107106672A (zh) 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体
WO2024104409A1 (zh) 一种含抗rankl-ngf双特异性抗体的药物组合物
HK40081275B (zh) Il-17ra融合蛋白、药物组合物、注射剂及其应用
HK40076796B (zh) 抗btla抗体药物组合物及其用途
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
BR112015020174B1 (pt) Anticorpo que liga gro-alfa, gro-beta, gro-gama, ena-78, gcp-2, nap-2 e il-8 humanos, seu uso e seu processo de produção, e molécula de dna
HK1259793B (zh) 用於提高血脑屏障转运的安全性的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination